Document is current

Article History

Received: 1 July 2020

Accepted: 7 July 2020

First Online: 9 September 2020

Ethics approval and consent to participate

: The Ethics Committee for investigation with medicinal products (CEim) of the Hospital Universitario La Princesa approved the study on March 9th, 2020. The Reference number of the ethical approval judgement is 4075. I certify that this trial has received ethical approval from the appropriate ethical committee as described above. Oral informed consent and request in urgent conditions according to the AEMPS (Spanish Agency for Drugs and Health Products) statement () will be recorded for all participants before enrolling in the study and will be registered in the electronic medical records.

: Not applicable.

: RGV declares no competing interests related to the present protocol; She reports she has received educational or research grants from Abbvie, BMS, Janssen Lilly, Novartis, MSD, Roche, and Sanofi; has received personal fees for advisory boards from Abbvie, Biogen, BMS, Celltrion, Mylan, Pfizer, Roche, Sandoz and Sanofi; has delivered presentations sponsored by BMS, Lilly, Pfizer, Sandoz and Sanofi; has received non-financial support for Abbvie, BMS, Lilly, MSD, Novartis, Pfizer and Sanofi, all outside the submitted work.FAS declares he has no competing interests.FRL is Medical Advisor at Sanofi Spain. He declares no competing interests related to the present protocol.IGA declares no competing interests related to the present protocol. He reports grants from ISCIII, grants from Fundación La Caixa; personal fees from Lilly, personal fees and non-financial support from BMS, personal fees from Sanofi, personal fees and non-financial support from Abbvie, grants, personal fees and non-financial support from Roche, non-financial support from MSD, non-financial support from Pfizer, non-financial support from Novartis, outside the submitted work;JSS declares he has no competing interests.